Veru Inc.
VERU · NASDAQ
Bulios Fair Price
$2.85
14.0% upside
Current Price
$2.5
According to Bulios Fair Price, VERU is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Veru Inc. (VERU) is an American pharmaceutical company focused on research, development, and commercialization of therapeutic products in the fields of urology and oncology. The company specializes in the treatment of oncological diseases, including prostate, breast, and other malignancies. Veru is also involved in the treatment of sexually transmitted infections and other urological indications. The company is dedicated to innovative therapeutic approaches and researching new drugs to improve the quality of life for patients and provide them with new treatment options. Veru Inc. has a strong foundation in medical research and development and collaborates with renowned experts in the fields of oncology and urology. Investing in Veru Inc. (VERU) shares may represent an attractive choice for investors who follow the pharmaceutical sector and seek a company with potential in innovative treatments for oncological and urological diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Mitchell S. Steiner
Employees
20
Headquarters
Miami
Upcoming events
Earnings
Upcoming earnings report
Earnings
Upcoming earnings report